These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

548 related items for PubMed ID: 29996800

  • 1. Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial.
    Sedhain A, Hada R, Agrawal RK, Bhattarai GR, Baral A.
    BMC Nephrol; 2018 Jul 11; 19(1):175. PubMed ID: 29996800
    [Abstract] [Full Text] [Related]

  • 2. Comparison of low-dose intravenous cyclophosphamide with oral mycophenolate mofetil in the treatment of lupus nephritis.
    Rathi M, Goyal A, Jaryal A, Sharma A, Gupta PK, Ramachandran R, Kumar V, Kohli HS, Sakhuja V, Jha V, Gupta KL.
    Kidney Int; 2016 Jan 11; 89(1):235-42. PubMed ID: 26489028
    [Abstract] [Full Text] [Related]

  • 3. Mizoribine versus mycophenolate mofetil or intravenous cyclophosphamide for induction treatment of active lupus nephritis.
    Feng X, Gu F, Chen W, Liu Y, Wei H, Liu L, Yin S, Da Z, Sun L.
    Chin Med J (Engl); 2014 Jan 11; 127(21):3718-23. PubMed ID: 25382325
    [Abstract] [Full Text] [Related]

  • 4. Mycophenolate mofetil or cyclophosphamide in indian patients with lupus nephritis: Which is better? A single-center experience.
    Mendonca S, Gupta D, Ali S, Gupta P.
    Saudi J Kidney Dis Transpl; 2017 Jan 11; 28(5):1069-1077. PubMed ID: 28937065
    [Abstract] [Full Text] [Related]

  • 5. A Comparison Of Mycophenolate Mofetil And Cyclophosphamide As Lupus Nephritis Induction Therapy.
    Gul H, Mushtaq MS, Salim B, Samreen S, Nasim A, Khan M.
    J Ayub Med Coll Abbottabad; 2020 Jan 11; 32(4):454-458. PubMed ID: 33225643
    [Abstract] [Full Text] [Related]

  • 6. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis.
    Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L.
    Chin Med J (Engl); 2002 May 11; 115(5):705-9. PubMed ID: 12133539
    [Abstract] [Full Text] [Related]

  • 7. Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH, Song GG.
    Lupus; 2015 Dec 11; 24(14):1520-8. PubMed ID: 26162684
    [Abstract] [Full Text] [Related]

  • 8. Current therapies for lupus nephritis in an ethnically heterogeneous cohort.
    Rivera TL, Belmont HM, Malani S, Latorre M, Benton L, Weisstuch J, Barisoni L, Tseng CE, Izmirly PM, Buyon JP, Askanase AD.
    J Rheumatol; 2009 Feb 11; 36(2):298-305. PubMed ID: 19040310
    [Abstract] [Full Text] [Related]

  • 9. Immunosuppressive treatment for proliferative lupus nephritis.
    Tunnicliffe DJ, Palmer SC, Henderson L, Masson P, Craig JC, Tong A, Singh-Grewal D, Flanc RS, Roberts MA, Webster AC, Strippoli GF.
    Cochrane Database Syst Rev; 2018 Jun 29; 6(6):CD002922. PubMed ID: 29957821
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva Lupus Management Study.
    Walsh M, Solomons N, Lisk L, Jayne DR.
    Am J Kidney Dis; 2013 May 29; 61(5):710-5. PubMed ID: 23375819
    [Abstract] [Full Text] [Related]

  • 11. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D, Rodrigues M, da Silva JAP, Inês L.
    Lupus; 2018 Jul 29; 27(8):1358-1362. PubMed ID: 29448882
    [Abstract] [Full Text] [Related]

  • 12. Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis.
    Arends S, Berden JH, Grootscholten C, Derksen RH, Berger SP, de Sévaux RG, Voskuyl AE, Bijl M, Dutch Working Party on SLE.
    Neth J Med; 2014 Nov 29; 72(9):481-90. PubMed ID: 25431394
    [Abstract] [Full Text] [Related]

  • 13. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide.
    Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L.
    Lupus; 2007 Nov 29; 16(9):707-12. PubMed ID: 17728363
    [Abstract] [Full Text] [Related]

  • 14. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.
    Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z.
    Nephrology (Carlton); 2005 Oct 29; 10(5):504-10. PubMed ID: 16221103
    [Abstract] [Full Text] [Related]

  • 15. Outcome and predictors of renal survival in patients with lupus nephritis: Comparison between cyclophosphamide and mycophenolate mofetil.
    Joo YB, Kang YM, Kim HA, Suh CH, Kim TJ, Park YW, Lee J, Lee JH, Yoo DH, Bae SC, Lee HS, Bang SY.
    Int J Rheum Dis; 2018 May 29; 21(5):1031-1039. PubMed ID: 29611341
    [Abstract] [Full Text] [Related]

  • 16. Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.
    Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.
    Rheumatology (Oxford); 2014 Sep 29; 53(9):1570-7. PubMed ID: 24505125
    [Abstract] [Full Text] [Related]

  • 17. Induction therapy for pediatric onset class IV lupus nephritis: Mycophenolate Mofetil versus Cyclophosphamide.
    Chbihi M, Eveillard LA, Riller Q, Brousse R, Berthaud R, Quartier P, Salomon R, Charbit M, Avramescu M, Biebuyck N, Dehoux L, Garcelon N, Duong-Van-Huyen JP, Bader-Meunier B, Boyer O.
    J Nephrol; 2023 Apr 29; 36(3):829-839. PubMed ID: 36208405
    [Abstract] [Full Text] [Related]

  • 18. Comparing the efficacy of low-dose vs high-dose cyclophosphamide regimen as induction therapy in the treatment of proliferative lupus nephritis: a single center study.
    Mehra S, Usdadiya JB, Jain VK, Misra DP, Negi VS.
    Rheumatol Int; 2018 Apr 29; 38(4):557-568. PubMed ID: 29450636
    [Abstract] [Full Text] [Related]

  • 19. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N, Ingsathit A, Rattanasiri S, Ngamjanyaporn P, Kasitanont N, Chawanasuntorapoj R, Pichaiwong W, Anutrakulchai S, Sangthawan P, Ophascharoensuk V, Avihingsanon Y, Sumethkul V.
    Lupus; 2018 Apr 29; 27(4):647-656. PubMed ID: 29105558
    [Abstract] [Full Text] [Related]

  • 20. Comparative efficacy and safety of mycophenolate mofetil and cyclophosphamide in the induction treatment of lupus nephritis: A systematic review and meta-analysis.
    Jiang YP, Zhao XX, Chen RR, Xu ZH, Wen CP, Yu J.
    Medicine (Baltimore); 2020 Sep 18; 99(38):e22328. PubMed ID: 32957400
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.